Recombinant Anti-CCL4/MIP-1 beta antibody [EP521Y] (ab45690)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP521Y] to CCL4/MIP-1 beta
- Suitable for: ELISA, IP, WB, ICC/IF
- Knockout validated
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-CCL4/MIP-1 beta antibody [EP521Y]
See all CCL4/MIP-1 beta primary antibodies -
Description
Rabbit monoclonal [EP521Y] to CCL4/MIP-1 beta -
Host species
Rabbit -
Tested applications
Suitable for: ELISA, IP, WB, ICC/IFmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human CCL4/MIP-1 beta aa 1 to the C-terminus (N terminal). The exact sequence is proprietary.
Database link: P13236 -
Positive control
- THP-1, Raw264.7
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP521Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab45690 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
IP |
1/60.
|
|
WB |
1/1000 - 1/500000. Detects a band of approximately 10 kDa (predicted molecular weight: 10 kDa).
|
|
ICC/IF |
1/100.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
IP
1/60. |
WB
1/1000 - 1/500000. Detects a band of approximately 10 kDa (predicted molecular weight: 10 kDa). |
ICC/IF
1/100. |
Target
-
Function
Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B. -
Sequence similarities
Belongs to the intercrine beta (chemokine CC) family. -
Post-translational
modificationsN-terminal processed form MIP-1-beta(3-69) is produced by proteolytic cleavage after secretion from peripheral blood lymphocytes. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 388372 Human
- Entrez Gene: 6351 Human
- Entrez Gene: 9560 Human
- Entrez Gene: 20303 Mouse
- Omim: 182284 Human
- Omim: 603782 Human
- Omim: 610757 Human
- SwissProt: P13236 Human
see all -
Alternative names
- MIP 1 beta antibody
- Secreted protein G 26 antibody
- ACT 2 antibody
see all
Images
-
All lanes : Anti-CCL4/MIP-1 beta antibody [EP521Y] (ab45690) at 1/1000 dilution
Lane 1 : Wild-type THP-1 Vehicle control + Brefeldin A (5 u/mL, 6 h) cell lysate
Lane 2 : Wild-type THP-1 Treated PMA (100 ng/mL, 56 h) + LPS (1 u/mL, 24 h) + Brefeldin A (5 u/mL, 6 h) cell lysate
Lane 3 : CCL4 knockout THP-1 Vehicle control + Brefeldin A (5 u/mL, 6 h) cell lysate
Lane 4 : CCL4 knockout THP-1 Treated PMA (100 ng/mL, 56 h) + LPS (1 u/mL, 24 h) + Brefeldin A (5 u/mL, 6 h) cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 10 kDa
Observed band size: 12 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-CCL4/MIP-1 beta antibody [EP521Y] staining at 1/1000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab45690 was shown to bind specifically to CCL4/MIP-1 beta. A band was observed at 12 kDa in wild-type THP-1 cell lysates with no signal observed at this size in CCL4 knockout cell line ab273719 (knockout cell lysate ab275512). To generate this image, wild-type and CCL4 knockout THP-1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
-
All lanes : Anti-CCL4/MIP-1 beta antibody [EP521Y] (ab45690) at 1/1000 dilution
Lane 1 : Untagged human CCL4 recombinant protein (aa24-92)
Lane 2 : Untagged human CCL4L recombinant protein (aa24-92)
Lane 3 : GST-tagged human CCL3 recombinant protein (aa27-92)
Lane 4 : GST-tagged human CCL3L recombinant protein 2*(aa28-93)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 10 kDa
Observed band size: 12 kDa why is the actual band size different from the predicted?
Exposure time: 5 secondsBlocking/Diluting buffer and concentration 5% NFDM /TBST
-
Immunocytochemistry/Immunofluorescence analysis of THP-1 (Human monocytic leukemia cell line) cells labeling CCL4/MIP-1 beta + CCL4L with ab45690 at 1/100. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. Cells were counter-stained with ab7291, ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 dilution. DAPI was used to stain nuclei blue.
The expression increased after treatment with Lipopolysaccharides (LPS), 100 ng/mL for 4 hours, followed by addition of Brefeldin A (1 μg/mL) for 3 hours.
-
All lanes : Anti-CCL4/MIP-1 beta antibody [EP521Y] (ab45690) at 1/1000 dilution
Lane 1 : Untreated THP-1 (human acute monocytic leukemia) cell lysate
Lane 2 : THP-1 treated with 100 nM Phorbol-12-myristate-13-acetate(PMA) overnight, then treated with Lipopolysaccharides (LPS) 100 ng/mL for 7 hours and then 1 µg/mL Brefeldin A was added for the last 3 hours, lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051)
Predicted band size: 10 kDa
Observed band size: 12 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking/Diluting buffer and concentration 5% NFDM /TBST.
CCL4/MIP-1 beta is induced in macrophages following exposure to bacterial LPS (PMID: 9848081).
-
ab45690 at 1/60 immunoprecipitating CCL4/MIP-1 beta + CCL4L in THP-1 (Human monocytic leukemia cell line) whole cell lysate observed at 12 KDa (lanes 1 and 2).
Lane 1 (input): THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1 μg/mL Brefeldin A was added for the last 3 hours whole cell lysate, 10μg
Lane 2 (+): ab45690 + THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1 μg/mL Brefeldin A was added for the last 3 hours whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab45690 in THP-1 treated with 100 nM PMA overnight, then treated with 100 ng/mL LPS for 7 hours and 1 μg/mL Brefeldin A was added for the last 3 hours whole cell lysate
For western blotting, ab45690 at 1/1000 and ab131366 VeriBlot for IP Detection Reagent (HRP) was used for detection (1/1000).
Blocking/Diluting buffer 5% NFDM/TBST
-
All lanes : Anti-CCL4/MIP-1 beta antibody [EP521Y] (ab45690) at 1/1000 dilution
Lane 1 : Untreated Raw264.7 (mouse abelson murine leukemia virus-induced tumor) whole cell lysate
Lane 2 : Raw264.7 (mouse abelson murine leukemia virus-induced tumor) treated with LPS 10µg/mL for 4 hours and then 1 µg/mL Brefeldin A was added for the last 3 hours lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 10 kDa
Exposure time: 3 minutesBlocking/Diluting buffer and concentration 5% NFDM /TBST
-
ELISA analysis of Human CCL4/MIP-1 beta recombinant protein at 500 ng/mL with ab45690. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab45690 has been referenced in 10 publications.
- Zhang X et al. Aged microglia promote peripheral T cell infiltration by reprogramming the microenvironment of neurogenic niches. Immun Ageing 19:34 (2022). PubMed: 35879802
- You S et al. SLC7A1 Overexpression Is Involved in Energy Metabolism Reprogramming to Induce Tumor Progression in Epithelial Ovarian Cancer and Is Associated with Immune-Infiltrating Cells. J Oncol 2022:5864826 (2022). PubMed: 36131790
- Yu YW et al. Retinoic Acid Receptor Gamma (RARγ) Promotes Cartilage Destruction through Positive Feedback Activation of NF-κB Pathway in Human Osteoarthritis. Mediators Inflamm 2022:1875736 (2022). PubMed: 36387933
- Yang L et al. Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer. Front Cell Dev Biol 9:596484 (2021). PubMed: 33777927
- Zhao H & He Y The Inhibitory Effect of Lysophosphatidylcholine on Proangiogenesis of Human CD34+ Cells Derived Endothelial Progenitor Cells. Front Mol Biosci 8:682367 (2021). PubMed: 34179086
- Gao M et al. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Front Immunol 11:366 (2020). PubMed: 32194569
- Ren F et al. Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer. J Cell Physiol 235:2738-2752 (2020). PubMed: 31498430
- Ren C et al. An effective and biocompatible polyethylenimine based vaginal suppository for gene delivery. Nanomedicine 20:101994 (2019). PubMed: 31028885
- Chen P et al. Identification and validation of four hub genes involved in the plaque deterioration of atherosclerosis. Aging (Albany NY) 11:6469-6489 (2019). PubMed: 31449494
- Zsiros E et al. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res 21:2840-50 (2015). PubMed: 25712684